Nurix therapeutics announces webcast to review data from its phase 1 clinical trials of btk degraders, nx-5948 and nx-2127, presented at the 65th american society of hematology (ash) annual meeting

San francisco, dec. 04, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the phase 1 clinical trials of its bruton's tyrosine kinase (btk) degrader programs, nx-5945 and nx-2127, which are being evaluated in patients with relapsed or refractory b cell malignancies, at 8:30 p.m. pst (11:30 p.m. est) on monday, december 11, 2023.
NRIX Ratings Summary
NRIX Quant Ranking